| P50 | author | Guido Kroemer | Q19508945 |
| | Jérôme Galon | Q3190910 |
| | Lorenzo Galluzzi | Q28317088 |
| | Laurence Zitvogel | Q28317098 |
| | Alexander M. M. Eggermont | Q28317101 |
| | Fernando Aranda | Q28317121 |
| | Erika Vacchelli | Q40778875 |
| | Wolf Hervé Fridman | Q40876588 |
| P2860 | cites work | First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting | Q21198874 |
| | Trial Watch | Q24618653 |
| | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 |
| | Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. | Q24655516 |
| | Decoding cell death signals in liver inflammation | Q26823299 |
| | Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy | Q26993238 |
| | Nivolumab plus ipilimumab in advanced melanoma | Q27852310 |
| | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 |
| | Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 |
| | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| | Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 |
| | PD-L2 is a second ligand for PD-1 and inhibits T cell activation | Q28202471 |
| | The danger model: a renewed sense of self | Q28214633 |
| | Adoptive immunotherapy for cancer: harnessing the T cell response | Q28262548 |
| | Hepatotoxicity with combination of vemurafenib and ipilimumab | Q28288255 |
| | Fcgamma receptors: old friends and new family members | Q28291895 |
| | Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody | Q41474839 |
| | Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy | Q41809357 |
| | Targeting PD-1/PD-L1 interactions for cancer immunotherapy | Q41817131 |
| | OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells | Q42060017 |
| | High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator | Q42204309 |
| | CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection | Q42214233 |
| | Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment | Q42403366 |
| | Trial Watch: Peptide vaccines in cancer therapy | Q42734544 |
| | Trial Watch: Lenalidomide-based immunochemotherapy | Q42737828 |
| | IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers | Q42779465 |
| | Trial Watch: Anticancer radioimmunotherapy | Q42847992 |
| | Trial watch: Dendritic cell-based interventions for cancer therapy | Q42867339 |
| | Trial Watch: Toll-like receptor agonists for cancer therapy | Q42969291 |
| | Cisplatin resistance associated with PARP hyperactivation | Q43703967 |
| | CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | Q43864036 |
| | The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses | Q44393406 |
| | Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone | Q46507429 |
| | Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. | Q47685354 |
| | Monoclonal antibodies: the story of a discovery that revolutionized science and medicine | Q47893912 |
| | A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia | Q53351927 |
| | Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. | Q53390272 |
| | Trial watch: Chemotherapy with immunogenic cell death inducers. | Q55658029 |
| | Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial | Q56897633 |
| | Trial watch: Monoclonal antibodies in cancer therapy | Q56932681 |
| | Phase I Trial of Multiple Large Doses of Murine Monoclonal Antibody CO17-1A. I. Clinical Aspects1 | Q68453399 |
| | Phase I clinical trial of CO17-1A monoclonal antibody | Q68803677 |
| | Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours | Q72522239 |
| | TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu | Q74070676 |
| | Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience | Q74171684 |
| | Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma | Q79346005 |
| | The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? | Q79990209 |
| | Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies | Q80556251 |
| | A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission | Q87355944 |
| | Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma | Q93630240 |
| | Tolerance, danger, and the extended family | Q29547532 |
| | Cancer immunotherapy via dendritic cells | Q29615444 |
| | Taking dendritic cells into medicine | Q29619243 |
| | Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 |
| | Immunogenic Cell Death in Cancer Therapy | Q29620118 |
| | Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer | Q29622818 |
| | A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma | Q30412791 |
| | Complement regulators and inhibitory proteins | Q33386110 |
| | Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma | Q33402203 |
| | A phase 1 study of lucatumumab, a fully human anti‐CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma | Q33402671 |
| | Immunotherapy: Vaccine trials in melanoma -- time for reflection | Q33434380 |
| | The roles of TGFβ in the tumour microenvironment | Q33630845 |
| | A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma | Q33829132 |
| | Complement and its role in innate and adaptive immune responses | Q34088142 |
| | Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance | Q34111451 |
| | Monoclonal antibodies: versatile platforms for cancer immunotherapy | Q34111693 |
| | Immunogenic cell death and DAMPs in cancer therapy | Q34311701 |
| | Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer | Q34362516 |
| | OX40 is a potent immune-stimulating target in late-stage cancer patients | Q34381674 |
| | Oncogenic stress sensed by the immune system: role of natural killer cell receptors | Q34473267 |
| | Transforming growth factor-beta in T-cell biology | Q34572232 |
| | Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study | Q34614776 |
| | Toll-like receptors and cancer | Q37340298 |
| | TGFbeta signalling: a complex web in cancer progression | Q37760038 |
| | Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies | Q37809159 |
| | Molecular mechanisms of the antitumor effects of anti-CD20 antibodies | Q37825142 |
| | Molecular mechanisms of cisplatin resistance | Q37926477 |
| | OX40 and CD30 signals in CD4+ T‐cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4+ T‐cell memory but not effector function | Q37948124 |
| | The secret ally: immunostimulation by anticancer drugs | Q37981038 |
| | Tremelimumab: a review of development to date in solid tumors | Q38085028 |
| | Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance | Q38124438 |
| | An immunosurveillance mechanism controls cancer cell ploidy | Q39269872 |
| | T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment | Q39300005 |
| | Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. | Q39457367 |
| | Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. | Q40456758 |
| | The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells | Q40725745 |
| | Breaking tumor-induced immunosuppression with 5'-triphosphate siRNA silencing TGFβ and activating RIG-I. | Q41219698 |
| | Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. | Q41228724 |
| | Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma | Q34647109 |
| | Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy | Q34656292 |
| | Identification of tumour-associated T-cell epitopes for vaccine development | Q34718188 |
| | Reassessing target antigens for adoptive T-cell therapy | Q34789569 |
| | New aspects of natural-killer-cell surveillance and therapy of cancer | Q34988265 |
| | Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity | Q35762422 |
| | Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. | Q35790354 |
| | Trial Watch: Monoclonal antibodies in cancer therapy | Q36038408 |
| | Trial watch: Chemotherapy with immunogenic cell death inducers | Q36038456 |
| | Trial Watch: Adoptive cell transfer immunotherapy | Q36057432 |
| | Trial Watch: Immunostimulatory cytokines | Q36057492 |
| | Trial Watch: Experimental Toll-like receptor agonists for cancer therapy | Q36194849 |
| | Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients | Q36252546 |
| | Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells | Q36373337 |
| | Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy | Q36373370 |
| | Trial watch: Dendritic cell-based interventions for cancer therapy | Q36388529 |
| | A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma | Q36425427 |
| | Trial watch: Peptide vaccines in cancer therapy | Q36476100 |
| | Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion | Q36527247 |
| | Therapeutic potential of immunostimulatory monoclonal antibodies | Q36532194 |
| | Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody | Q36544926 |
| | Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors | Q36643696 |
| | Immunostimulatory monoclonal antibodies for cancer therapy | Q36717901 |
| | The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection | Q36737159 |
| | Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients | Q36806268 |
| | Trial Watch: Adoptive cell transfer for anticancer immunotherapy | Q36887833 |
| | Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours | Q36896203 |
| | Negative signaling by inhibitory receptors: the NK cell paradigm | Q36983705 |
| | Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma | Q37003295 |
| | TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells. | Q37028027 |
| | Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells | Q37256962 |
| | Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia | Q37257024 |
| | A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma | Q37325331 |
| | The role of TNF superfamily members in T-cell function and diseases | Q37332068 |
| P433 | issue | 1 | |
| P921 | main subject | antibody | Q79460 |
| | monoclonal antibody | Q422248 |
| P304 | page(s) | e27297 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy | |
| P478 | volume | 3 | |